Hematology
Position Statement: Standardizing care to manage bleeding disorders in adolescents with heavy menses
21 Oct, 2020 | 09:07h | UTC
Meta-analysis: The association of D-dimers with mortality, intensive care unit admission or ARDS in patients hospitalized with COVID-19
20 Oct, 2020 | 01:37h | UTC
New studies show reduced prevalence and severity of SARS-CoV-2 infection in ABO blood group O
18 Oct, 2020 | 23:16h | UTCStudy 1: Reduced prevalence of SARS-CoV-2 infection in ABO blood group O – Blood Advances
Commentaries: People with blood type O may have lower risk of Covid-19 infection and severe illness, two new studies suggest – CNN AND Studies offer new evidence for possible link between blood type and COVID-19 susceptibility – American Society of Hematology
Guideline: Management and prevention of anemia (acute bleeding excluded) in adult critical care patients
18 Oct, 2020 | 22:52h | UTC
Commentary on Twitter
Latest guidelines for anemia 🩸in critically ill patients by @SigLasocki published in @AccpmJ
📈 what threshold?
🩸 how many RBCs?
💉EPO as a substitute?➡️check the Full 📃 for the answers !https://t.co/sJIIbunwKB#CriticalCare #ICU #Anemia #MedTwitter #AnesthTwitter https://t.co/AMD5xZnWDr
— Alice Blet, MD, PhD (@BletAlice) October 15, 2020
Cochrane living systematic review: Not enough evidence to recommend convalescent plasma for people with COVID‐19
16 Oct, 2020 | 09:34h | UTC
Commentary on Twitter
Just updated: @CochraneCollab living review investigates the use of convalescent plasma to treat people with COVID-19: https://t.co/Or5qmxki8H “We remain very uncertain about the effectiveness & safety of using convalescent plasma for people with #COVID19".
— The Cochrane Library (@CochraneLibrary) October 13, 2020
Study: Negative D-dimer safely rules out DVT as a stand-alone test
16 Oct, 2020 | 09:26h | UTCNegative D-dimer safely ruled out DVT as a stand-alone test – Blood Advances
Non-respiratory presentations of COVID-19, a clinical review
14 Oct, 2020 | 09:33h | UTC
Meta-analysis: Risk of venous thromboembolism in patients with COVID‐19
6 Oct, 2020 | 00:54h | UTC
Commentaries on Twitter
In a new #RPTH paper, researchers performed a meta-analysis of #VTE risk in #COVID19 patients: 22.7% prevalence in ICU vs. 7.9% in non-ICU patients. Other subgroup analyses reveal heterogeneity and interesting trends…@Cihan_Ay_MD @FlorianMoik NEW: https://t.co/24IWOm5qTe pic.twitter.com/HjnSYq9YKz
— RPTH (@RPTHjournal) September 30, 2020
Meta-analysis of #clotting events in 66 studies including 28173 patients with #COVID19. High #VTE & #PE prevalence in ICU patients indicates a need for thromboprophylaxis research! Read the results at #RPTH by @Cihan_Ay_MD @FlorianMoik https://t.co/24IWOlNPuE @thrombosisday pic.twitter.com/V4Pn2ssBH3
— RPTH (@RPTHjournal) October 5, 2020
What we have found was a trend of decreased VTE rates over time. Earlier studies reported slightly higher VTE rates than more recent ones. What could be the reason? Experience dealing with COVID19 and improved preventive strategies? https://t.co/YDjRyvNmK6 https://t.co/y3Uj5x3QRI pic.twitter.com/0HcFQvMJB8
— Cihan Ay (@Cihan_Ay_MD) September 26, 2020
[Abstract Only] Meta-analysis: Direct oral anticoagulants for cancer-associated venous thromboembolism
28 Sep, 2020 | 01:22h | UTC
Association of red blood cell distribution width with mortality risk in hospitalized adults with SARS-CoV-2 infection
24 Sep, 2020 | 09:32h | UTCCommentary: Simple blood test can predict severity of COVID-19 for some patients – University of Texas Health Science Center at Houston AND Routine blood test may identify patients at risk for severe COVID-19 – UPI
Commentary on Twitter
Death in #COVID19: JAMA Open
In lots of dzs RDW >14.5% robustly risk stratifies pts w/in illness. True in #COVID! Mortality w/ nl RDW 11% vs. 31% with high RDW (9% ⬆️ risk per 0.5% increase in RDW). BEST predictor next to Age!https://t.co/aZJ3p488cN#medtwitter #tipsfornewdocs pic.twitter.com/967g2HElYH— WesElyMD (@WesElyMD) September 23, 2020
Clinical review: Emerging immunotherapies in multiple myeloma
23 Sep, 2020 | 14:33h | UTCEmerging immunotherapies in multiple myeloma – The BMJ
Commentary on Twitter
Despite advances in treatment in the past 20yrs, multiple myeloma remains an incurable disease. This review summarizes the evidence of these various immunotherapies, their mechanism of action, and data on treatments' safety and efficacy #BMJEducation https://t.co/JWeMlJ89YR
— The BMJ (@bmj_latest) September 22, 2020
A comprehensive update on aspirin management during noncardiac surgery
22 Sep, 2020 | 09:24h | UTCA Comprehensive Update on Aspirin Management During Noncardiac Surgery – Anesthesia & Analgesia
Comparison of published guidelines for management of coagulopathy and thrombosis in critically ill patients with COVID 19
20 Sep, 2020 | 21:30h | UTC
Editorial: Convalescent plasma for Covid-19
20 Sep, 2020 | 21:29h | UTCConvalescent plasma for covid-19 – The BMJ
Commentary on Twitter
Last month the US FDA authorised the emergency use of convalescent plasma for hospital patients with covid-19. What evidence underpinned the FDA’s controversial decision? And will the authorisation make it more difficult to recruit participants for RCTS? https://t.co/PMO13J2IOq
— The BMJ (@bmj_latest) September 19, 2020
The pooled prevalence of pulmonary embolism in patients with COVID-19
18 Sep, 2020 | 09:37h | UTCThe pooled prevalence of pulmonary embolism in patients with COVID-19 – Intensive Care Medicine
Commentary on Twitter
Pulmonary embolism in #COVID19, be careful! quantitative meta-analysis ->
pooled prevalence in pts undergoing #PE diagnosis 28%
higher pooled prevalence in pts admitted to #ICU vs those admitted to non-ICU: 19 vs 9%
Open access @yourICM #COVIDFOAM #FOAMcc https://t.co/dUqKAVoeCV pic.twitter.com/fvmQnTlv1M— Intens Care Med (@yourICM) September 15, 2020
Investigating whether blood type is linked to COVID-19 risk
17 Sep, 2020 | 09:26h | UTCInvestigating Whether Blood Type Is Linked to COVID-19 Risk – JAMA
Commentary on Twitter
Researchers find no relationship between blood type and severe #COVID19, despite early studies suggesting possible higher risk for those with type A. “The basic science on this is extremely weak.” https://t.co/tYreg896DK
— JAMA (@JAMA_current) September 17, 2020
Multisystem effects of COVID-19: A concise review for practitioners
16 Sep, 2020 | 09:14h | UTCMultisystem effects of COVID-19: A concise review for practitioners – Postgraduate Medicine
Preliminary randomized trial evaluated recombinant human granulocyte colony–stimulating factor for patients with COVID-19 and lymphopenia
11 Sep, 2020 | 01:36h | UTCInvited Commentary: Immune Stimulation With Recombinant Human Granulocyte Colony–Stimulating Factor for Coronavirus Disease 2019 (COVID-19)—Beware of Blind Spots
Commentary on Twitter
Preliminary findings from a randomized clinical trial suggest that rhG-CSF treatment should be studied in larger trials and in a broader range of patients with #COVID19 https://t.co/SjsoWOkEXg
— JAMA Internal Medicine (@JAMAInternalMed) September 10, 2020
Clinical outcomes in young adults hospitalized with COVID-19
10 Sep, 2020 | 09:49h | UTCClinical Outcomes in Young US Adults Hospitalized With COVID-19 – JAMA Internal Medicine
Editorial: Regardless of Age, Obesity and Hypertension Increase Risks With COVID-19
Commentary: Obesity greatest risk factor for young adults with COVID-19 – MedicalXpress
Commentary on Twitter
18 to 34 years old #COVID19 hospitalized outcomes:
✔️21% intensive care,
✔️10% mechanical ventilation
✔️2.7% died.
✔️Morbid obesity, hypertension & diabetes associated with⬆️risks of adverse events.
✔️+ ½ requiring hospitalization: Black or Hispanic⚓️https://t.co/kcs2cery7s pic.twitter.com/ASVB943Bhc
— Medtor #COVID19 (@Medtorek) September 9, 2020
[Preprint] Randomized trial: Convalescent plasma not associated with improved outcomes in Covid-19
9 Sep, 2020 | 09:41h | UTC
Commentary on Twitter
Convalescent Plasma Randomized Controlled Trial (PLACID Trial) in the Management of Moderate #COVID19 (pre-print)
👉 “not associated with reduction in mortality or progression to severe COVID-19”
Link: https://t.co/2ZXnfemsas@GermHunterMD @MackayIM @CT_Bergstrom #IDTwitter pic.twitter.com/yZuOxVhbjL
— Alvin (@alvie_barr) September 8, 2020
COVID-19 is, in the end, an endothelial disease
8 Sep, 2020 | 01:11h | UTCCOVID-19 is, in the end, an endothelial disease – European Heart Journal
Commentary on Twitter
COVID as an infectious disease of the “endothelium”, the lining of blood vessels, transmitted pre-sympyomatically. Explains the sepsis syndrome; explains the clotting/bleeding; explains the kidney failure.
What a nasty, nasty disease.https://t.co/5hlfL5Iik9
— David Fisman (@DFisman) September 7, 2020
Cohort study: COVID-19 prevalence and mortality in patients with cancer and the effect of primary tumor subtype and patient demographics
6 Sep, 2020 | 21:42h | UTCCommentaries: New study describes which cancer patients are more vulnerable to COVID-19 – University of Birmingham AND COVID-19 Prevalence and Mortality in Patients With Cancer in the UK – The ASCO Post
Systematic review: Association between D-Dimer levels and mortality in patients with COVID-19
6 Sep, 2020 | 21:37h | UTC
Randomized trial: Preoperative intravenous iron to treat anemia 10–42 days before major abdominal surgery does not reduce the need for blood transfusion
6 Sep, 2020 | 21:28h | UTC
Commentary on Twitter
Startling finding. In a blinded RCT, preop iron transfusion did not ⬇️complications, or a ⬇️transfusions after major abdominal surgery. While Hb ⬆️, no real tangible benefit occurred.
Periop medicine & optimization is complicated! #colorectalsurgery https://t.co/q0HhR3JCy3— Ahmer Karimuddin (@ahmerkarimuddin) September 5, 2020
Review: Coagulopathy of Covid-19
4 Sep, 2020 | 02:14h | UTCCoagulopathy of Coronavirus Disease 2019 – Critical Care Medicine
Commentary on Twitter
What you need to know about #Covid19 #coagulopathy is all in one place – @CCM. This will help target your anticoagulation plans for COVID care. @SCCM https://t.co/gKUbc995ra
— Lewis J. Kaplan (@SCCMPresident) September 1, 2020